A phase 3 therapy, zoliflodacin, has shown to be noninferior in a late stage trial. The therapy's manufacturer, Innoviva Speciality Therapeutics, is presenting data at this week's ID Week. The company's CMO David Altarac, MD, offers some insights on the therapy and the timeline for filing the paperwork for prospective FDA approval.
GS-1720 could offer a weekly dosing option for individuals living with HIV, supported by a good safety profile with no serious adverse events, which has led to the initiation of a Phase 2 study.
At this week’s ID Week, Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota, for the prevention of recurrence.
Tina Tan, MD, FAAP, FIDSA, FPIDS underscores the importance of education and global collaboration in antimicrobial stewardship to tackle the escalating threat of AMR, and her takeaways from the UN General Assembly High-Level Meeting on Antimicrobial Resistance.
Ammara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.
Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.
Uzma Syed, MD, DO discussed how various factors increase women’s susceptibility to AMR, the importance of policies, and the need for culturally specific education and advocacy to improve health outcomes.
The benefits, challenges, and prospects of wastewater data in enhancing public health strategies against AMR.
Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.
Debra Goff, PharmD, discusses her advocacy around this topic and bringing the stewardship message to dentists about how antibiotic prescribing practices have changed and getting them to recalibrate their thinking and actions in their field.
James Graham, CEO discussed the company's progress in developing a new antibiotic for sepsis and diabetic foot ulcers.
Benjamin Park, MD, offers insights on the federal agency’s role in AMR.
Britton Strickland, MD discusses innovations in microbiome research and their impact on antimicrobial resistance.
Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.
Jennifer Ronholm, PhD, discusses the novel concept of microbiome protection to create healthier animals and reduce antimicrobial usage.
Akhila Kosaraju, MD, addresses overcoming key challenges in antibiotic development using AI, a nonprofit model, and supportive policies.
Amanda Jezek, of the Infectious Diseases Society of America (IDSA), offers some insight on the prospective bill in Congress, as well as other AMR initiatives the organization is involved in.
Insights from Catherine Bertrand Ferrandis, DVM, on the role of One Health and interdisciplinary collaboration.
After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.
Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.
The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.
The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.
While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.
A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).
During today's CDC Advisory Committee on Immunization Practices (ACIP) meeting, committee members voted to recommend the FDA-authorized 2024-2025 COVID-19 vaccines for individuals aged 6 months and older. Additionally, they reaffirmed the existing influenza vaccination guidelines for the 2024-2025 season.
Brii Biosciences presented new data from Phase 2 trials for chronic hepatitis B at EASL Congress 2024, revealing insights into the efficacy of BRII-179 as botha combined therapy and an additional treatment.
Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offering insights into microbiota alteration and prospects for management.
At Digestive Disease Week, Paul Feuerstadt MD, FACG, AGAF and fellow investigators explore the potential impact of non-antibiotic medications on gut health and their association with recurrent CDI.
A comparative study presented MAD-ID, The Antimicrobial Stewardship Meeting examining the effectiveness of ceftaroline and vancomycin in addressing this challenge.
A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.
